RefleXion Medical is a pioneering company in the field of radiopharmaceuticals, transforming traditional cancer treatment by integrating tumor biology into external beam radiotherapy. With its FDA Breakthrough Device designation for lung tumors, RefleXion's SCINTIX® therapy automates the targeting and management of motion in treating lung and bone tumors, including those that are metastatic. The company collaborates with leading radiopharmaceutical firms to co-develop disease-specific radiotracers aimed at late-stage cancer treatment. RefleXion is committed to innovation and excellence in customer support, providing advanced medical equipment and services to enhance clinical outcomes.